Purdue Pharma L.P.’s $8.3bn settlement with the US Department of Justice bolsters its efforts to emerge from bankruptcy as a new entity free of the liability from its opioid marketing.
The company has agreed to plead guilty to three felony counts, pay a criminal fine of $3.54bn plus $2bn in criminal forfeiture, and pay a civil settlement of $2.8bn to resolve DOJ’s criminal and civil investigations of its marketing of OxyContin and other opioid products